Literature DB >> 21760590

Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine.

M T Voso, E Fabiani, A Piciocchi, C Matteucci, L Brandimarte, C Finelli, E Pogliani, E Angelucci, G Fioritoni, P Musto, M Greco, M Criscuolo, L Fianchi, M Vignetti, V Santini, S Hohaus, C Mecucci, G Leone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21760590     DOI： 10.1038/leu.2011.170

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  19 in total

Review 1.  Why methylation is not a marker predictive of response to hypomethylating agents.

Authors:  Maria Teresa Voso; Valeria Santini; Emiliano Fabiani; Luana Fianchi; Marianna Criscuolo; Giulia Falconi; Francesco Guidi; Stefan Hohaus; Giuseppe Leone
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

Review 2.  Predicting response to epigenetic therapy.

Authors:  Marianne B Treppendahl; Lasse S Kristensen; Kirsten Grønbæk
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 3.  DNA Hypomethylating Drugs in Cancer Therapy.

Authors:  Takahiro Sato; Jean-Pierre J Issa; Patricia Kropf
Journal:  Cold Spring Harb Perspect Med       Date:  2017-05-01       Impact factor: 6.915

4.  MBASED: allele-specific expression detection in cancer tissues and cell lines.

Authors:  Oleg Mayba; Houston N Gilbert; Jinfeng Liu; Peter M Haverty; Suchit Jhunjhunwala; Zhaoshi Jiang; Colin Watanabe; Zemin Zhang
Journal:  Genome Biol       Date:  2014-08-07       Impact factor: 13.583

5.  A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies.

Authors:  Kirsten Grønbæk; Carsten Müller-Tidow; Giovanni Perini; Sören Lehmann; Marianne Bach Treppendahl; Ken Mills; Christoph Plass; Brigitte Schlegelberger
Journal:  Haematologica       Date:  2012-04-04       Impact factor: 9.941

6.  TET family dioxygenases and the TET activator vitamin C in immune responses and cancer.

Authors:  Xiaojing Yue; Anjana Rao
Journal:  Blood       Date:  2020-09-17       Impact factor: 22.113

Review 7.  The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.

Authors:  E Solary; O A Bernard; A Tefferi; F Fuks; W Vainchenker
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528

Review 8.  Epigenetics of myelodysplastic syndromes.

Authors:  R Itzykson; P Fenaux
Journal:  Leukemia       Date:  2013-11-19       Impact factor: 11.528

9.  BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.

Authors:  Thomas Cluzeau; Guillaume Robert; Nicolas Mounier; Jean Michel Karsenti; Maeva Dufies; Alexandre Puissant; Arnaud Jacquel; Aline Renneville; Claude Preudhomme; Jill-Patrice Cassuto; Sophie Raynaud; Frederic Luciano; Patrick Auberger
Journal:  Oncotarget       Date:  2012-04

10.  TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings.

Authors:  Andrea Patriarca; Donatella Colaizzo; Gianluca Tiscia; Raffaele Spadano; Silvia Di Zacomo; Antonio Spadano; Ida Villanova; Maurizio Margaglione; Elvira Grandone; Alfredo Dragani
Journal:  Biomed Res Int       Date:  2013-05-25       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.